API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

1

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

27.00

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

11

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

TaiMed Biologics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo® (Ibalizumab-uiyk) in the Middle East and North Africa Region

Details:

Under the terms of this agreement, AcedrA will register, promote and commercialize Trogarzo (Ibalizumab-uiyk), a CD4-directed post-attachment HIV-1 inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1) infection, in the MENA region.

Lead Product(s): Ibalisumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: AcedrA BioPharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 18, 2024

ASK
US

Upload
your Marketing & Sales content

Theratechnologies

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV

Details:

sBLA submission with FDA for Trogarzo (Ibalizumab-uiyk), a CD4-directed post-attachment HIV-1 inhibitor is approved for the treatment of adults infected with MDR HIV-1 in Europe.

Lead Product(s): Ibalisumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 06, 2021

ASK
US

Upload
your Marketing & Sales content

Theratechnologies

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Theratechnologies Announces Reimbursement Agreement in Italy for Trogarzo® for Eligible Patients With Multi-Drug Resistant HIV-1

Details:

Theratechnologies plans to launch Trogarzo® on a country-by-country basis across Europe as it gains reimbursement in each individual country. In addition, the Company received regulatory approval in Israel for Trogarzo® and is working to secure pricing and reimbursement.

Lead Product(s): Ibalisumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Trogarzo

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Italian Medicines Agency

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 26, 2021

ASK
US

Upload
your Marketing & Sales content